AstraZeneca India R&D Head Balganesh Tanjore On "Drug Hunting" In India To Be At Vanguard Of Innovation
This article was originally published in PharmAsia News
Executive Summary
Balganesh Tanjore heads AstraZeneca PLC's innovation efforts in India from the company's Bangalore-based R&D center. The senior scientist is known for his pioneering studies in the field of tuberculosis, having worked on several new compounds. Tanjore keeps a low profile but those in the field of medical research respect his contributions and appreciate his efforts in putting together a very robust innovative infrastructure in India. In a rare media intervew, Tanjore spoke to PharmAsia News' India bureau about "drug hunting" in India, including linking up with academic institutions for better solutions.
You may also be interested in...
End Of An Era? AstraZeneca Closes India Research Site Focused On Tropical Diseases
Stakeholders are asking if AstraZeneca remains committed to neglected tropical diseases after the company announces it will close its Indian research unit. The center was the last remaining big pharma basic research center in India.
India Should Play Up R&D Strengths But Build "China-like" Infrastructure - BIO India Conference
HYDERABAD - Indian companies are more entrepreneurially driven than their Chinese counterparts, and although a noticeable switch in mindset toward innovation is welcomed, the government needs to participate more in building infrastructure to raise confidence levels for global companies to funnel more research work to India, multinational companies urged
India Should Play Up R&D Strengths But Build "China-like" Infrastructure - BIO India Conference
HYDERABAD - Indian companies are more entrepreneurially driven than their Chinese counterparts, and although a noticeable switch in mindset toward innovation is welcomed, the government needs to participate more in building infrastructure to raise confidence levels for global companies to funnel more research work to India, multinational companies urged